- Around 70% of people who have obstructive sleep apnea also have obesity.
- A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro improved symptoms of obstructive sleep apnea.
- Tirzepatide, the main ingredient in these medications, reduced symptom severity by nearly two-thirds.
- Weight loss was reported in 20% of participants taking tirzepatide.
Sleep apnea occurs when a person has difficulty or stops breathing when sleeping. The most common type of sleep apnea is called obstructive sleep apnea.
Researchers estimate that about 70% of people who have obstructive sleep apnea also have obesity.
The latest numbers from the World Health Organization (WHO) report that obesity affects
Recently reported results from a phase 3 clinical trial found
The results of this clinical trial have yet to be published in a peer-reviewed scientific journal.
Eli Lilly and Company — maker of both Mounjaro and Zepbound — recently reported results from the SURMOUNT-OSA clinical trials examining the use of tirzepatide for improving obstructive sleep apnea symptoms.
The trial included 469 study participants from the United States, Brazil, China, Australia, Germany, and four other nations.
Participants had moderate-to-severe obstructive sleep apnea and obesity and were either unable or unwilling to use positive airway pressure (PAP) therapy — examined during SURMOUNT-OSA Study 1 — or were and planned to continue to use PAP therapy during the trial, which was looked at during SURMOUNT-OSA Study 2.
For both studies, participants received either a dose of tirzepatide or a placebo for 52 weeks.
Upon analysis, researchers found that participants who received tirzepatide injections experienced a significantly reduced
Read the full article here
